Drug Trial Radar · NCT04795037
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Jul 15, 2021
Primary completion
Mar 2, 2022
Study completion Jun 25, 2022
Sponsor
- Lead sponsor
- Curacle Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- KCRN Research, LLC
- First posted
- Mar 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
Conditions
- Diabetic Macular Edema
Interventions
CU06-1004, Single doseDrug
Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)* *Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5
CU06-1004, Multiple dosesDrug
Multiple doses of CU06-1004, 7 days, 3 dose levels*, oral capsule *The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD
PlaceboDrug
Placebo matched to CU06-1004, oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number and severity of treatment emergent adverse events (TEAEs)Time frame: From the date of first dose through 7 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.